STOCK TITAN

Akebia Therapeutics (AKBA) awards RSUs and stock options to director Adams

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Akebia Therapeutics, Inc. director Adrian Adams reported awards of equity-based compensation. He received 35,700 shares of common stock as restricted stock units that were granted at no cash price and increase his direct holdings to 236,200 common shares after the award.

Adams was also granted a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share, expiring on June 17, 2036. Both the restricted stock units and the stock option are scheduled to vest in full on the first anniversary of the grant date, or earlier immediately before the first annual stockholder meeting after the grant, subject to his continuous service to the company.

Positive

  • None.

Negative

  • None.
Insider ADAMS ADRIAN
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to buy) 53,600 $0.00 --
Grant/Award Common Stock 35,700 $0.00 --
Holdings After Transaction: Stock Option (Right to buy) — 53,600 shares (Direct, null); Common Stock — 236,200 shares (Direct, null)
Footnotes (1)
  1. The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
RSU grant 35,700 shares Restricted stock units granted to director on June 17, 2026
Option grant size 53,600 shares Stock option covering common shares granted on June 17, 2026
Option exercise price $1.02 per share Conversion or exercise price for new stock option
Option expiration June 17, 2036 Expiration date of stock option grant
Shares held after grant 236,200 shares Common stock directly held by Adrian Adams after RSU grant
restricted stock units financial
"The restricted stock units (the "RSUs") were granted by the Issuer"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2023 Stock Incentive Plan financial
"were granted by the Issuer pursuant to its 2023 Stock Incentive Plan"
Non-Employee Director Compensation Program financial
"as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program"
Stock Option financial
"The option to purchase shares of the Issuer's common stock (the "Stock Option")"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting financial
"will vest in full (100%) on the first anniversary of the grant date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ADAMS ADRIAN

(Last)(First)(Middle)
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST ST.

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/17/2026A35,700(1)A$0.00236,200D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$1.0206/17/2026A53,60006/17/2027(2)06/17/2036Common Stock53,600$0.0053,600D
Explanation of Responses:
1. The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
2. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Remarks:
/s / Carolyn Rucci, attorney-in-fact for Adrian Adams06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Adrian Adams receive from Akebia Therapeutics (AKBA)?

Adrian Adams received 35,700 restricted stock units and a stock option for 53,600 shares. Both awards were granted as part of director compensation and are tied to Akebia’s 2023 Stock Incentive Plan.

What is the exercise price of Adrian Adams’ new Akebia (AKBA) stock option?

The new stock option for Adrian Adams has an exercise price of $1.02 per share. It covers 53,600 shares of Akebia common stock and was granted under the company’s 2023 Stock Incentive Plan.

When do Adrian Adams’ Akebia (AKBA) restricted stock units vest?

The 35,700 restricted stock units granted to Adrian Adams vest 100% on the first anniversary of the grant date. They can also vest earlier, immediately before the first annual stockholder meeting after the grant, if that occurs sooner.

When do Adrian Adams’ new Akebia (AKBA) stock options become exercisable?

The 53,600-share stock option becomes fully exercisable on the first anniversary of the grant date. It may vest earlier immediately before the first annual stockholder meeting after the grant, provided Adrian Adams maintains continuous service.

How many Akebia (AKBA) common shares does Adrian Adams hold after these grants?

After receiving the new restricted stock units, Adrian Adams holds 236,200 shares of Akebia common stock directly. This figure reflects his position following the equity grant reported in the Form 4.

What plan governs Adrian Adams’ new Akebia (AKBA) equity awards?

Both the restricted stock units and the stock option were granted under Akebia’s 2023 Stock Incentive Plan. The terms also follow the Fifth Amended and Restated Non-Employee Director Compensation Program for board members.